Join us for vision 73’s inaugural event on March 20th in Central London. While full details will be announced soon, you can register via the link.
Priority registration for this event will be given to researchers in physics, neuroscience, materials science, and engineering if space becomes limited. However, we encourage everyone passionate about the future of BCIs to register, as we’re already planning to expand capacity and customise the content for future events. Don’t miss your chance to be part of this transformative journey!
Schedule
18.00 registration
18.15 opening presentation from vision 73
18.30 Jacob T. Robinson, Reflections on a research and entrepreneurial journey and an intersection of physics and neurotech (online – venue-exclusive livestream)
19.00 Jamie Brannigan, Where are we now? An overview of iBCI clinical trials, challenges, and opportunities (offline)
20.00 Refreshments
Details
Jacob T. Robinson
Jacob Robinson is the co-founder and CEO of Motif Neurotech, a company developing neural devices to treat and track mental illness. He is also a professor of Electrical and Computer Engineering at Rice Univeristy. Jacob holds a Ph.D. in Applied Physics from Cornell and completed his postdoc at Harvard. Prior to founding Motif, Jacob led a research group at Rice University for 12 years, publishing over 60 peer-reviewed papers in top journals like Nature and Science. His lab’s innovations in brain-computer interfaces (BCI) and bioelectronics attracted over $40 million in federal and private funding. Although now leading Motif full-time, Jacob remains a professor at Rice. His work has earned him the Charles Duncan Award, the DARPA Young Faculty Award, and the Materials Today Rising Star Award. He previously co-chaired the IEEE Brain Initiative and is a senior member of IEEE and IEEE EMBS. Motif Neurotech aims to pioneer psychiatric BCI technologies under his leadership.
https://www.robinsonlab.com/jacob-t-robinson
Jamie Brannigan
Jamie Brannigan is a clinician scientist who trained at the University of Cambridge, where he also completed an undergraduate degree in neuroscience. He is currently a clinician scientist at Oxford University. Jamie’s primary research interests are the clinical translation of implantable brain-computer interfaces, and the development of novel endovascular approaches to BCI. Jamie has several years of BCI experience within the context of both academia and industry. In addition to his role at Oxford, Jamie holds an honorary research fellowship at UCL, where he collaborates on studies aimed at assessing the clinical needs and patient preferences for implantable BCI devices.
vision 73 